SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against agilon health, inc. - AGL

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for alleged securities fraud and unlawful business practices, following significant financial disclosures that negatively impacted the company's stock price [1][4]. Financial Performance - Agilon conducted its initial public offering on April 15, 2021, selling over 53 million shares at $23.00 per share [2]. - In Q3 2023, Agilon reported medical margins of $108 million, significantly below analyst expectations, partly due to $9 million in previously unreported claims [3]. - The company experienced a $6 million loss in adjusted EBITDA for the quarter, which also missed analyst estimates, and lowered its 2023 expected medical margins [3]. - On January 5, 2024, Agilon revealed higher prior medical expenses, leading to a further reduction in its 2023 expected medical margin and a withdrawal of its 2026 guidance [4]. - For the year 2023, Agilon's medical margin was reported at just $299 million, falling short of the reduced range of $340 million to $360 million [5]. - The company slashed its 2024 medical margin guidance by 27% and adjusted EBITDA guidance from a projected gain of $40 to $60 million to a loss of $15 to $60 million [5]. Stock Price Impact - Following the Q3 2023 results announcement, Agilon's stock price fell by $2.23, or 13%, closing at $14.66 per share [3]. - After the January 5, 2024 announcement, the stock price dropped by $3.45, nearly 29%, closing at $8.63 per share [4]. - On March 1, 2024, after the disclosure of further financial issues, the stock price fell by $0.44, or 7%, closing at $6.04 per share, with subsequent declines reaching a low of $5.66 per share [5].